Yahoo India Web Search

Sign In

Search results

  1. www.sobi.comSobi - Transforming the lives of people with rare diseases

    At Sobi, we are dedicated to transforming the lives of people with rare and debilitating diseases. Meet some of the people who inspire us. Their real-life experiences and stories reinforce our commitment to patients.

  2. en.wikipedia.org › wiki › Swedish_Orphan_BiovitrumSwedish Orphan Biovitrum - Wikipedia

    Swedish Orphan Biovitrum AB is an international biopharmaceutical company dedicated to treatments in the areas of haematology, immunology and specialty care, based in Stockholm, Sweden. In 2020 it had a revenue of SEK 15.261 billion and 1,509 employees.

  3. www.linkedin.com › company › sobiSobi - Swedish Orphan Biovitrum AB (publ) | LinkedIn

    Sobi is a specialised international biopharmaceutical company transforming the lives of people with rare diseases. We provide sustainable access to innovative therapies in the areas of haematology,...

  4. www.nature.com › articles › d43747/020/00680-6Leading the way in rare diseases - Nature

    Swedish Orphan Biovitrum AB (publ) (Sobi), an international specialty health-care company, aims to be recognized as a global leader in providing access to innovative treatments that transform the...

  5. finance.yahoo.com › quote › BIOVFSwedish Orphan Biovitrum AB (publ) (BIOVF) - Yahoo Finance

    Find the latest Swedish Orphan Biovitrum AB (publ) (BIOVF) stock quote, history, news and other vital information to help you with your stock trading and investing.

  6. www.prnewswire.com › news-releases › fda-approves-once-weekly-efanesoctocog-alfa-aFDA approves once-weekly efanesoctocog alfa, a new class of high...

    Feb 24, 2023 · Efanesoctocog alfa (formerly BIVV001) is a novel and investigational recombinant factor VIII therapy with the potential to deliver near-normal factor activity levels for most of the week,...

  7. www.prnewswire.com › news-releases › sobi-publishes-q1-2023-report-continued-solidSobi publishes Q1 2023 report: Continued solid progress - PR...

    Apr 27, 2023 · STOCKHOLM, April 27, 2023 /PRNewswire/ -- Swedish Orphan Biovitrum AB (publ) (Sobi®) today announced its report for the first quarter of 2023. First quarter 2023. Total revenue SEK 5,239 M...

  8. www.sobi.com › en › aboutAbout | Sobi

    Sobi is a specialised international biopharmaceutical company transforming the lives of people with rare and debilitating diseases. Inspired by caring, powered by science, we are dedicated to: Maintaining our commitment to patients, our employees, and society.

  9. www.prnewswire.com › news-releases › sobi-publishes-q1-2022-report-301535114Sobi publishes Q1 2022 report - PR Newswire

    Apr 28, 2022 · STOCKHOLM, April 28, 2022 /PRNewswire/ -- Swedish Orphan Biovitrum AB (publ) (Sobi®) today announced its report for the first quarter of 2022. January – March 2022

  10. www.bloomberg.com › news › articlesAdvent, GIC Bid $8 Billion for Swedish Orphan-Drug Maker Sobi

    Sep 2, 2021 · Private equity firm Advent International and Singapore wealth fund GIC agreed to buy drugmaker Swedish Orphan Biovitrum AB for 69 billion kronor ($8 billion) in the largest buyout of a Nordic...